CLINICAL TRIALS PROFILE FOR TELAPREVIR
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Telaprevir
Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|---|
New Formulation | NCT01511432 ↗ | A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects | Completed | Vertex Pharmaceuticals Incorporated | Phase 1 | 2012-01-01 | The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets. |
>Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Telaprevir
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00336479 ↗ | Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C | Completed | Vertex Pharmaceuticals Incorporated | Phase 2 | 2006-06-01 | Study the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) and Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels |
NCT00372385 ↗ | Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C | Completed | Vertex Pharmaceuticals Incorporated | Phase 2 | 2006-08-01 | Compare the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) with and without Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels |
NCT00420784 ↗ | A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3) | Completed | Vertex Pharmaceuticals Incorporated | Phase 2 | 2007-02-01 | The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an investigational drug, Telaprevir (VX-950) or Placebo, with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a, Pegasys®), and Ribavirin (RBV, Copegus®) in people with genotype 1 hepatitis C who have not achieved a Sustained Viral Response (SVR) with a previous treatment of interferon therapy. |
NCT00509210 ↗ | Study of Telaprevir in Subjects With Hepatic Impairment | Completed | Vertex Pharmaceuticals Incorporated | Phase 1 | 2007-09-01 | The purpose of this study is to assess the safety and pharmacokinetics of Telaprevir following administration of multiple oral doses to subjects with moderate and severe hepatic impairment. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Telaprevir
Condition Name
Clinical Trial Locations for Telaprevir
Trials by Country
Clinical Trial Progress for Telaprevir
Clinical Trial Phase
Clinical Trial Sponsors for Telaprevir
Sponsor Name